Six at-home ketamine therapy providers compared by dose model, integration support, pricing, and published outcomes data.
Online ketamine therapy has become the fastest-growing segment of the ketamine treatment market. Telehealth providers can evaluate you, prescribe compounded ketamine, and ship it to your door — a meaningful reduction in access barriers compared to IV infusion centers. However, the market now includes dozens of providers with widely different clinical standards, pricing models, and outcomes data. This guide evaluates the six providers with the most transparent protocols and the largest published patient bases.
We evaluated each provider on: clinical evaluation rigor (who conducts it and what it covers), integration or therapy support (is there a therapist, or just a prescriber?), pricing transparency (is the full cost visible before you sign up?), outcomes data (has the provider published or shared clinical outcome metrics?), and patient accessibility (state availability, minimum requirements).
Joyous is among the most affordable legal at-home ketamine programs in the US, with pricing starting at approximately $129/month (only Kalm Health advertises a lower starting price, at $124/month). Their model differs from other providers: instead of a full "journey dose" (200–400 mg), Joyous uses a microdose or sub-perceptual protocol (typically 30–100 mg) taken daily or several times per week. This is designed to minimize the dissociative experience while maintaining antidepressant effects over time.
We could not confirm a peer-reviewed study of Joyous patients; the large 2022 Hull et al. dataset (n=1,247) comes from a provider the abstract does not name, and several of its authors list Mindbloom as their affiliation (see the Mindbloom section).
Mindbloom is one of the most recognized names in at-home ketamine therapy. Their program uses sublingual ketamine tablets at full therapeutic doses (typically 200–400 mg), paired with a custom music playlist, eye mask, and app-guided session support — designed to create a structured psychedelic experience at home.
The Mindbloom clinical team includes nurse practitioners and prescribing physicians. A clinician-led evaluation is required before admission. Optional integration therapy sessions are available as an add-on with their network of therapists. The 2022 Hull et al. cohort (n=1,247) in the Journal of Affective Disorders was written by researchers that include Mindbloom-affiliated authors.
Nue Life Health places the most emphasis on therapeutic depth of the major at-home ketamine providers. Their program includes preparation sessions with a licensed therapist, ketamine sessions at home, and structured integration sessions after each dosing session — a model that more closely mirrors the protocol used in clinical trials than most at-home competitors.
Nue Life also has a corporate wellness arm and has partnered with several health systems. Their clinical team includes psychiatrists, therapists, and nurses. Nue Life has published preliminary outcome data but has not yet published a peer-reviewed study as of 2026.
Wondermed offers a straightforward telehealth-to-home-delivery model. Their intake is conducted via a structured intake form reviewed by a clinician, followed by a video consultation. Approved patients receive compounded ketamine lozenges shipped directly. The program is primarily self-directed rather than therapist-guided.
Wondermed's pricing is transparent and there are no hidden subscription fees. They are one of the clearer pricing models in the market. However, the lack of built-in integration support means it suits patients who have existing mental health care providers to work with alongside the ketamine program.
Innerwell takes a more personalized psychiatric approach than most at-home ketamine providers. Rather than a fixed protocol, their team — which includes psychiatrists and psychiatric nurse practitioners — designs a treatment plan based on the patient's specific diagnosis, history, and response. They treat depression, PTSD, anxiety, and OCD.
Innerwell also supports patients who are already on Spravato (esketamine) to ensure that their at-home ketamine program integrates with rather than conflicts with their existing treatment. This is uncommon among at-home providers.
Klinic (formerly operating as KetaMed in some markets) has expanded to serve a broad range of US states, including several where other providers have limited telehealth prescribing infrastructure. Their intake process is clinician-led and their pricing is competitive.
Klinic's model includes a medication management layer — the prescribing clinician monitors response and can adjust dosing over time. They do not include integration therapy in the base price but offer referrals to therapists in their network.
Operating across 33 US states, Better U is a telehealth service that prescribes ketamine for at-home use, shipped as oral ketamine tablets with a provider-directed nasal-spray option also available. Patients take sessions at a higher journey-dose level in the psychedelic range. The protocol does not follow a microdose schedule like Joyous.
Care begins with a screening by a licensed clinician, and a peer support person must be present during dosing sessions. The program centers on the medication itself plus a small number of integration-coaching sessions and self-guided exercises. It is not a full structured psychotherapy program, and Better U does not bill insurance.
Kalm Health offers guided at-home ketamine treatment through a telehealth model with no clinic visits required. The program includes a consultation with a licensed clinician and follow-up monitoring. Medication is shipped by mail as at least a one-month supply of ketamine troches or orally-dissolving tablets, delivered in 7 to 10 business days.
Patients receive ongoing messaging access to their prescribing clinician through a patient portal. Kalm Health does not bill insurance directly, but its services are eligible for reimbursement through an HSA or FSA. Kalm advertises a price-match guarantee that beats a competitor's verified lower price by 20 percent.
| Provider | Dose model | Therapy included | Outcomes data | Approx. monthly cost | Best for |
|---|---|---|---|---|---|
| Joyous | Microdose (daily) | No (app support) | No peer-reviewed study confirmed | ~$129–$169/mo | Low cost; minimal dissociation |
| Mindbloom | Full-dose (sublingual) | Optional add-on | Peer-reviewed cohort (Hull 2022); Mindbloom-affiliated authors | ~$198–$268/mo | Structured full-dose home experience |
| Nue Life Health | Full-dose | Yes — prep + integration | Preliminary (not peer-reviewed) | ~$250–$350/mo | Deepest therapy integration |
| Wondermed | Full-dose | No | Limited | ~$220–$280/kit | Simple, self-directed access |
| Innerwell | Personalized | Varies by plan | Internal, not published | Contact for pricing | Personalized psychiatry; PTSD/OCD |
| Klinic | Full-dose | No (referral only) | Limited | ~$180–$250/mo | Broad state availability |
| Better U | Full-dose (journey) | Coaching sessions included | Not published | ~$100/session (~$500 for 5) | Full journey-dose model; required peer support |
| Kalm Health | Full-dose | No | Not published | ~$124/mo | Lowest advertised price; HSA/FSA-eligible |
At-home compounded ketamine programs offer meaningfully lower cost and convenience compared to IV infusion centers, but they have real tradeoffs. IV ketamine delivers the drug directly into the bloodstream with no first-pass metabolism — achieving higher peak plasma concentrations and more predictable bioavailability than sublingual lozenges.
At-home lozenges have highly variable absorption (30–50% bioavailability vs. close to 100% IV), meaning the effective dose varies more between sessions. For patients with more complex clinical profiles — severe TRD, PTSD, or co-occurring conditions — IV ketamine in a supervised clinical setting may be the more appropriate starting point. See our ketamine guide for a full breakdown of the delivery models and the evidence behind each. For side effects and safety questions, see ketamine side effects and the at-home ketamine safety checklist; to compare with the FDA-approved nasal spray, see Spravato vs ketamine. Wondering whether ketamine is safe with SSRIs, benzodiazepines or alcohol? Use the medication safety checker and read the psychedelic medication safety guide; do not change any medication without your prescriber. Questions about ketamine and workplace drug testing are answered in the ketamine guide.
Best overall value: Joyous for budget; Mindbloom for full-dose experience at a mid-range price. Mindbloom has published outcomes data, which is rare among at-home ketamine providers.
Best if therapy integration matters: Nue Life Health. The included therapist sessions make this the closest analog to the clinic-plus-therapist model used in most clinical trials.
Best for personalized psychiatric care: Innerwell. If your situation is clinically complex, the psychiatrist-level personalization is worth the extra cost.
Not sure if at-home is right for you? Use our depression treatment path tool to compare ketamine with other treatment options based on your specific history, or the ketamine provider finder to see options in your state.
Yes. Compounded ketamine can be legally prescribed by a licensed US physician or nurse practitioner and dispensed by a licensed US compounding pharmacy, and telehealth evaluations are currently permitted under temporary DEA flexibilities (see the in-person evaluation answer below). All providers on this list operate within this framework. You cannot legally purchase ketamine without a valid US prescription from a licensed prescriber who has evaluated you clinically. Spravato (esketamine) is separately FDA-approved but requires in-office administration — it cannot be taken at home.
At-home ketamine therapy costs approximately $124–$350 per month, depending on the provider and whether integration therapy is included. Kalm Health advertises the lowest starting price at approximately $124/month, and Joyous starts at approximately $129–$169/month. Advertised prices vary and can exclude add-ons and refills. Mindbloom costs approximately $198–$268/month. Nue Life Health, which includes integration therapy, costs approximately $250–$350/month. IV ketamine at an in-person clinic is not included in these programs — that runs $400–$800 per infusion and is not covered by most insurance.
Spravato (esketamine nasal spray) is covered by Medicare and most major commercial insurance plans for treatment-resistant depression under FDA-approved criteria. Compounded at-home ketamine is generally not covered by insurance because it is prescribed off-label. IV ketamine infusions are also generally not covered. Some HSA/FSA accounts cover at-home ketamine as an eligible expense — verify with your plan administrator.
IV ketamine delivers the drug directly into the bloodstream, achieving close to 100% bioavailability and predictable dosing. At-home sublingual lozenges have approximately 30–50% bioavailability — higher than oral ingestion but lower and more variable than IV. The dissociative experience at equivalent effective doses is similar, but the self-directed environment at home means no medical supervision during the session. For patients with complex psychiatric profiles — severe PTSD, high medical risk — IV ketamine in a supervised clinic may be more appropriate.
The largest published clinical datasets on at-home telehealth ketamine come from studies authored by Mindbloom-affiliated researchers. Hull et al. (2022) in the Journal of Affective Disorders analyzed 1,247 patients, and a 2024 paper in the same journal evaluated 11,441 patients. Neither study included a blinded placebo control, and the authors disclosed employment or affiliations with Mindbloom. There are no confirmed peer-reviewed studies of Joyous patients, and the strongest evidence for ketamine in depression remains in academic randomized trials of clinic-administered ketamine.
Yes, a Drug Enforcement Administration (DEA) registered practitioner can legally prescribe ketamine without an in-person evaluation under current federal telemedicine flexibilities. The Ryan Haight Act (21 U.S.C. 829(e)) normally requires an in-person evaluation to prescribe a controlled substance over the internet, but the statute exempts qualifying telemedicine. Under a fourth temporary extension published in the Federal Register on December 31, 2025, the DEA and the Department of Health and Human Services (HHS) extended these flexibilities through December 31, 2026. Because this flexibility is temporary and state laws also apply, readers should check current DEA rules and their state's requirements.
Yes, the Food and Drug Administration (FDA) published a compounding risk alert on October 10, 2023, warning of potential risks associated with compounded ketamine products for psychiatric disorders. The alert noted that neither compounded drugs nor ketamine are FDA-approved for psychiatric disorders, and safe and effective dosing has not been established. It also warned that compounded ketamine obtained through telemedicine platforms for at-home use may put patients at risk without monitoring by an onsite health care provider for sedation and dissociation. The FDA has separately approved esketamine (Spravato), which is a different product from compounded ketamine.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.